Abstract
A study of the epithelial mucin marker MCA was made in 233 patients with breast cancer. Only 6% of 72 patients with Stage I-III disease had a raised MCA (greater than 15 U ml-1) when assessed following surgical treatment of the primary tumour. Raised levels of MCA occurred in one out of 20 (10%) patients with stable local recurrence, and six out of ten (60%) patients with progressive local recurrence. In 115 patients with metastases 89 (77%) had a raised MCA, tumour extent and disease activity both influenced the MCA level. The change of MCA level during the treatment of 11 cases of local recurrence and 55 cases of metastatic disease showed a 64 and 84% concordance respectively with the change in clinical status. Coincidental measurement of MCA and bone scans showed a raised MCA in one out of 63 (1.5%) patients with negative or equivocal scans, and 26 out of 35 (74%) with positive scans. MCA provides a useful marker for the monitoring of the treatment of local recurrence and metastatic disease, and an independent indicator of the effects of changes in treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bieglmayer C., Szepesi T., Neunteufel W. Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA 15.3 and carcinoembryonic antigen. Cancer Lett. 1988 Nov;42(3):199–206. doi: 10.1016/0304-3835(88)90305-9. [DOI] [PubMed] [Google Scholar]
- Bray K. R., Koda J. E., Gaur P. K. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res. 1987 Nov 15;47(22):5853–5860. [PubMed] [Google Scholar]
- Cooper E. H., Forbes M. A., Hancock A. K., Price J. J., Parker D. An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer. Br J Cancer. 1989 May;59(5):797–800. doi: 10.1038/bjc.1989.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eskelinen M., Tikanoja S., Collan Y. Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor. Anticancer Res. 1989 Mar-Apr;9(2):437–439. [PubMed] [Google Scholar]
- Hayes D. F., Zurawski V. R., Jr, Kufe D. W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986 Oct;4(10):1542–1550. doi: 10.1200/JCO.1986.4.10.1542. [DOI] [PubMed] [Google Scholar]
- Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- Kiang D. T., Greenberg L. J., Kennedy B. J. Tumor marker kinetics in the monitoring of breast cancer. Cancer. 1990 Jan 15;65(2):193–199. doi: 10.1002/1097-0142(19900115)65:2<193::aid-cncr2820650202>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- Marino P., Buccheri G., Preatoni A., Ferrigno D., Cori P., Rosti A., Mozzi R., Moroni G. A. Soluble interleukin-2 receptor: a new prognostic marker in lung cancer. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):151–154. [PubMed] [Google Scholar]
- Rasoul-Rockenschaub S., Zielinski C. C., Kubista E., Vavra N., Pospischil E., Staffen A., Czerwenka K., Aiginger P., Spona J. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. Eur J Cancer Clin Oncol. 1989 Jul;25(7):1067–1072. doi: 10.1016/0277-5379(89)90390-8. [DOI] [PubMed] [Google Scholar]
- Steger G. G., Mader R., Derfler K., Moser K., Dittrich C. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. Klin Wochenschr. 1989 Aug 17;67(16):813–817. doi: 10.1007/BF01725197. [DOI] [PubMed] [Google Scholar]